Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study.

Background: Little is known on the current global prevalence of atopic dermatitis (AD) in the pediatric population.

Objective: To estimate the real-world global prevalence of AD in the pediatric population and by disease severity.

Methods: This international, cross-sectional, web-based survey of children and adolescents (6 months to <18 years old) was conducted in the following 18 countries: North America (Canada, United States), Latin America (Argentina, Brazil, Columbia, Mexico), Europe (France, Germany, Italy, Spain, United Kingdom), Middle East and Eurasia (Israel, Saudi Arabia, Turkey, United Arab Emirates, Russia), and East Asia (Japan, Taiwan).

The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada.

Background: Cross-sectional data on patient burden in adults with atopic dermatitis (AD) from real-world clinical practice are limited.

Objective: This study compared patient-reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe.

Methods: This study included adults (18-65 years) diagnosed with AD by dermatologists, general practitioners or allergists.

Epidemiology of atopic dermatitis in adults: Results from an international survey.

Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD).

Objective: To estimate the prevalence of AD in adults and by disease severity.

Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan.

Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.

Purpose: The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in the real-world setting. Secondary objectives were to describe the factors that influence the decision to prescribe a first and second-line antitumour treatment.

Diabetes injectable therapy: type 2 diabetes management in Danish practice.

Most diabetes care is done by GPs in Denmark. This study aimed to identify the barriers for GPs in initiating injectable therapies and reasons for referral to specialists. The web interview conducted included 85 GPs and 30 specialists experienced in type 2 diabetes (T2D).